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The late Colombian Nobel Prize–win-
ning author Gabriel García Márquez wrote 
“Love in the Time of Cholera,” a complex 
depiction of the struggle to love during 
an infectious epidemic (1). In the novel, 
a rational, responsible physician devoted 
to science is working to eradicate cholera 
but is pitted against a passionate, emo-
tional, and impulsive man who wins some 
of the personal battles. Our current battle 
against the novel coronavirus 2019 dis-
ease (COVID-19) caused by SARS-CoV-2 
will require both rational medical science 
as well as passionate and rapid risk-tak-
ing. The current COVID-19 pandemic has 
affected everyone but presents profound 
consequences for patients with kidney dis-
ease, health care providers, and biomedical 
researchers. In this Viewpoint, I will dis-
cuss a number of kidney-specific aspects 
of COVID-19 infection, noting therapeutic 
and basic research opportunities.
SARS-CoV-2 entry into kidney 
epithelial cells via ACE2
Angiotensin-converting enzyme 2 (ACE2) 
serves as a receptor for SARS-CoV-1 and 
SARS-CoV-2 (2, 3). ACE2 is expressed in 
the lung alveolar epithelial cells, oral and 
nasal mucosa, and other organs, including 
renal epithelial cells and bladder cells (4, 
5). Activation of the renin-angiotensin-al-
dosterone system is countered by ACE2. 
SARS-CoV-2 can bind to renal epithelial 
cells, injure these cells, and subsequent-
ly disrupt whole body fluid, acid-base, 
and electrolyte homeostasis. By injur-
ing kidney epithelial cells, SARS-CoV-2 
also disrupts kidney endocrine produc-
tion of erythropoietin and vitamin D and 
impairs blood pressure regulation. Viral 
entry into renal epithelial cells suggests 
the possibility that the kidney could also 
become a viral reservoir once clearance 
occurs elsewhere and that urine could 
be an infectious factor. It will be import-
ant to determine if other kidney-resident 
cells, such as podocytes, interstitial cells, 
and immune cells, become infected. Giv-
en widespread use of ACE inhibitors and 
angiotensin receptor blockers for hyper-
tension and cardiac and renal diseases, 
it will also be important to determine 
whether stopping or adding these drugs is 
beneficial in acute COVID-19 infections 
(6). At this point, many medical societies 
have suggested that the health benefits 
of ACE inhibitors or angiotensin recep-
tor blockers outweigh potential risks in 
COVID-19, but this is an important unan-
swered question.
COVID-19 and dialysis
Over 500,000 patients in the US are 
currently on dialysis (7). These patients 
have depressed immune systems, and 
those using in-center hemodialysis visit 
densely populated outpatient units three 
times per week. Patients on kidney dialy-
sis usually have other comorbidities, such 
as diabetes, hypertension, and cardiac 
diseases. Rapid responses to COVID-19 
by hemodialysis units, which are experi-
enced in limiting the viral spread of HIV, 
hepatitis B and C, and other pathogens, 
will decrease but not prevent its spread. 
Early in the pandemic, COVID-19–posi-
tive symptomatic hemodialysis patients 
were often transferred to hospitals, both 
to manage their acute illness and to 
reduce the risk of spread at their dialy-
sis units. With the spread of COVID-19, 
dedicated outpatient dialysis units will 
be needed to care for growing numbers 
of COVID-19–positive stable hemodial-
ysis patients. Increasing the use of home 
dialysis with home hemodialysis or peri-
toneal dialysis, already a goal of the US 
Health and Human Services to reduce 
health care costs and improve health out-
comes (8), should be hastened to reduce 
incidence of COVID-19 infections.
An early Chinese report character-
ized hemodialysis patients from January 
14, 2020, the day the first COVID-19 
case was confirmed in the hemodialysis 
center at Wuhan University, to February 
17, 2020. During this period, the authors 
reported that 37 of 230 hemodialysis 
patients (16.1%) and 4 of 33 staff members 
(12.1%) were diagnosed with COVID-19. 
Six COVID-19–positive patients died 
within a one-month span in early 2020, 
but the causes of death may not have 
been directly linked to COVID-19 (9). 
Dialysis patients with COVID-19 had 
less lymphopenia, lower serum levels 
of inflammatory cytokines, and milder 
clinical disease than nondialysis patients 
affected by COVID-19 infection. It is not 
yet clear whether hemodialysis patients 
have increased transmissibility/infec-
tion rates or worse clinical outcomes. 
COVID-19 infection leads to systemic 
inflammation and elevation of D-dimers, 
protein fragments associated with degra-
dation of fibrin in blood clots. D-dimers 
can clot dialysis circuits, possibly more 
often under the conditions of reduced 
blood flow seen during inpatient continu-
ous dialysis treatments. It will be import-
ant to quickly devise plans to keep dial-
ysis patients safe during the COVID-19 
pandemic, determine how to best dialyze 
them, and elucidate the unique relation-
ships between uremia and infection (10).
COVID-19 and kidney 
transplantation
Almost all kidney transplant patients are 
on lifelong immunosuppressive medica-
tion, which makes them more susceptible 
to infections and malignancies. During 
the early months after transplantation, 
very high levels of immunosuppression 
are needed, often with lymphocyte deple-
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be crucial not to sacrifice scientific rigor 
in our collective effort to address the new 
challenges facing patients with kidney dis-
eases in the COVID-19 pandemic.
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